艾拉戈利治疗子宫内膜异位症女性的长期结局:两项扩展研究结果
两项扩展研究评估艾拉戈利(口服非肽类促性腺激素释放激素拮抗剂)在子宫内膜异位症相关疼痛女性中治疗12个月的疗效与安全性,共入组569例。治疗12个月后,痛经应答率在150 mg每日一次组为52.1%(Elaris EM-IV为550.8%),200 mg每日两次组为78.2%(Elaris EM-IV为575.9%);非经期盆腔痛应答率分别为67.5%(Elaris EM-IV为566.4%)和69.1%(Elaris EM-IV为567.2%);性交痛应答率分别为45.2%(Elaris EM-IV为45.9%)和60.0%(Elaris EM-IV为58.1%)。潮热是最常见的不良事件,骨密度较基线下降、血脂较基线升高,未观察到子宫内膜不良发现。
要点
- 艾拉戈利长期治疗可持续减轻痛经、非经期盆腔痛和性交痛。
- 安全性特征与雌激素水平降低一致,未发现新的安全性问题。
- 潮热为最常见不良事件,骨密度下降和血脂升高在12个月治疗中观察到。
核心结论
- 长期艾拉戈利治疗可持续减轻痛经、非经期盆腔痛和性交痛,安全性特征与雌激素水平降低一致,未发现与长期使用相关的新安全性问题。
研究设计与样本
- Elaris EM-III和EM-IV为扩展研究,在两项为期6个月的双盲、安慰剂对照3期试验后额外评估6个月治疗(连续治疗12个月),艾拉戈利剂量为150 mg每日一次和200 mg每日两次。
- 共入组569例参与者,Elaris EM-III入组时间在2012年12月28日至2014年10月31日之间,Elaris EM-IV入组时间在2014年5月27日至2016年1月6日之间。
主要发现
- 治疗12个月后,Elaris EM-III痛经应答率在150 mg每日一次组为52.1%(Elaris EM-IV为550.8%),在200 mg每日两次组为78.2%(Elaris EM-IV为575.9%)。
- Elaris EM-III非经期盆腔痛应答率在150 mg每日一次组为67.5%(Elaris EM-IV为566.4%),在200 mg每日两次组为69.1%(Elaris EM-IV为567.2%)。
- 治疗12个月后,Elaris EM-III性交痛应答率在150 mg每日一次组为45.2%(Elaris EM-IV为45.9%),在200 mg每日两次组为60.0%(Elaris EM-IV为58.1%)。
- 潮热是最常见的不良事件,治疗12个月后观察到骨密度较基线下降和血脂较基线升高,未观察到子宫内膜不良发现。
关键数值与推荐
- 共同主要疗效终点为基于平均每月痛经和非经期盆腔痛评分的应答者比例(临床意义疼痛减轻且补救镇痛药使用稳定或减少)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To evaluate the efficacy and safety of elagolix, an oral, nonpeptide gonadotropin-releasing hormone antagonist, over 12 months in women with endometriosis-associated pain. METHODS: Elaris Endometriosis (EM)-III and -IV were extension studies that evaluated an additional 6 months of treatment after two 6-month, double-blind, placebo-controlled phase 3 trials (12 continuous treatment months) with two elagolix doses (150 mg once daily and 200 mg twice daily). Coprimary efficacy endpoints were the proportion of responders (clinically meaningful pain reduction and stable or decreased rescue analgesic use) based on average monthly dysmenorrhea and nonmenstrual pelvic pain scores. Safety assessments included adverse events, clinical laboratory tests, and endometrial and bone mineral density assessments. The power of Elaris EM-III and -IV was based on the comparison to placebo in Elaris EM-I and -II with an expected 25% dropout rate. RESULTS: Between December 28, 2012, and October 31, 2014 (Elaris EM-III), and between May 27, 2014, and January 6, 2016 (Elaris EM-IV), 569 participants were enrolled. After 12 months of treatment, Elaris EM-III responder rates for dysmenorrhea were 52.1% at 150 mg once daily (Elaris EM-IV 550.8%) and 78.2% at 200 mg twice daily (Elaris EMIV 575.9%). Elaris EM-III nonmenstrual pelvic pain responder rates were 67.5% at 150 mg once daily (Elaris EM-IV 566.4%) and 69.1% at 200 mg twice daily (Elaris EM-IV 567.2%).”After 12 months of treatment, Elaris EM-III dyspareunia responder rates were 45.2% at 150 mg once daily (Elaris EM-IV=45.9%) and 60.0% at 200 mg twice daily (Elaris EM-IV=58.1%). Hot flush was the most common adverse event. Decreases from baseline in bone mineral density and increases from baseline in lipids were observed after 12 months of treatment. There were no adverse endometrial findings. CONCLUSION: Long-term elagolix treatment provided sustained reductions in dysmenorrhea, nonmenstrual pelvic pain, and dyspareunia. The safety was consistent with reduced estrogen levels and no new safety concerns were associated with long-term elagolix use. CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov, NCT01760954 and NCT02143713.
引用
- Surrey E, Taylor HS, Giudice L, et al. Long-Term Outcomes of Elagolix in Women With Endometriosis: Results From Two Extension Studies. Obstet Gynecol. 2018. PMID: 29889764. doi:10.1097/AOG.0000000000002675
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。